Vimarsana
Biggest News Aggregation in the World

Page 34 - Contract Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Contract Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Contract Development Today - Breaking & Trending Today

Fujirebio and Sysmex Expand CDMO Partnership into the Field of Neurodegenerative Diseases under Their Immunoassay Collaboration - Vimarsana News

Fujirebio and Sysmex Expand CDMO Partnership into the Field of Neurodegenerative Diseases under Their Immunoassay Collaboration

Fujirebio Holdings Inc. President CEO Goki Ishikawa and Sysmex Corporation President Kaoru Asano today announced that they have entered into an agreement to expand their Contract Development and Manufacturing Organization CDMO partnership for Sysmexs Automated Immunoassay System HISCLSeries.

Unither Pharmaceuticals celebrates 30 years of innovation and expertise - Vimarsana News

Unither Pharmaceuticals celebrates 30 years of innovation and expertise

/PRNewswire/ -- Unither Pharmaceuticals, a leading CDMO (Contract Development and Manufacturing Organization), celebrates 30 years in business. In 1993,...

Unither Pharmaceuticals celebrates 30 years of innovation and expertise - Vimarsana News

Unither Pharmaceuticals celebrates 30 years of innovation and expertise

/PRNewswire/ -- Unither Pharmaceuticals, a leading CDMO (Contract Development and Manufacturing Organization), celebrates 30 years in business. In 1993,...

Unither Pharmaceuticals celebrates 30 years of innovation and expertise - Vimarsana News

Unither Pharmaceuticals celebrates 30 years of innovation and expertise

Unither Pharmaceuticals, a leading CDMO (Contract Development and Manufacturing Organization), celebrates 30 years in business. In 1993, Unither Pharmaceuticals began operations by acquiring a 17-man pharmaceutical plant that produced 3...

Piramal Pharma to see 13% CAGR in revenue, 40% in Ebitda in FY23-26: Jefferies - Vimarsana News

Piramal Pharma to see 13% CAGR in revenue, 40% in Ebitda in FY23-26: Jefferies

Investment banking firm expects pharma major’s revenue to reach Rs 10,164.6 crore by FY26